MetaCap

Foghorn Therapeutics Inc. (FHTX)

NASDAQ: FHTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.72-0.06 (-3.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

FHTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$103.14M
52-week range
1.66 – 7.61
Day range
1.66 – 1.80
Volume / Avg
919.93K / 843.73K
Beta
—

52-week range

$1.66$7.61

FHTX stock today

Foghorn Therapeutics (FHTX) closed at $1.72 on Nov 20, down 3.37% (-$0.06), versus the S&P 500's 3.70% decline. At this level, FHTX sits near the bottom of its 52-week range of $1.66 to $7.61: 77.4% below the high, set on Aug 20, 2026 and 3.6% above the low. FHTX is down 68.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 62.8%.

Foghorn Therapeutics trades at 19.1x its trailing twelve-month earnings per share of $0.09.

Summary generated from market data by MetaCap's automated system. Methodology

About Foghorn Therapeutics

Company profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Adrian H. B. Gottschalk
Headquarters
Watertown, MA
Employees
106
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Foghorn Therapeutics generated $30.9 million in revenue, up 36.8% from fiscal 2024. Foghorn Therapeutics reported a net loss of $74.3 million, compared with a loss of $86.6 million a year earlier. Operating margin was -279.5%.

Foghorn Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$30.91M$22.60M$34.16M$19.23M$1.32M
Growth+36.75%-33.83%+77.63%+1357.77%+206.74%
Net income$-74.28M$-86.62M$-98.43M$-108.88M$-101.32M
EPS (diluted)$-1.18$-1.58$-2.34$-2.62$-2.73

Analyst forecast

Forecast

Consensus (10 analysts)

buy

Avg. price target

$4.17+142.44%

  • Strong buy 0
  • Buy 5
  • Hold 5
  • Sell 0
  • Strong sell 0

Target range

Low $2.00High $5.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$0.80 vs $-0.23
Surprise
+447.83%

FHTX news

All FHTX news

Foghorn Therapeutics peers

Health Care sector
FHTX peer companies
CompanyPrice% ChgMarket capCompare
GNLXGenelux Corporation2.17-4.82%$103.36Mvs FHTX
ORGOOrganogenesis Holdings Inc. Class A0.7716-2.23%$100.16Mvs FHTX
NERVMinerva Neurosciences Inc2.00-5.66%$99.67Mvs FHTX
AKBAAkebia Therapeutics Inc.0.3855-8.71%$107.04Mvs FHTX
CNTNCanton Strategic Holdings Inc.1.21-1.63%$98.78Mvs FHTX
UNCYUnicycive Therapeutics Inc.3.35-5.10%$97.77Mvs FHTX
BGMBGM Group Ltd. Class A8.130.00%$108.57Mvs FHTX
SPRBSpruce Biosciences Inc.38.00-6.15%$109.21Mvs FHTX

Indexes, lists and sector

Foghorn Therapeutics stock FAQ

What is Foghorn Therapeutics's stock price today?

FHTX last traded at $1.72 as of Nov 20, 4:00 PM EST, down 3.37% on the day. Prices are delayed at least 15 minutes.

What is FHTX's P/E ratio?

FHTX trades at a trailing P/E ratio of 19.11.

Who is Foghorn Therapeutics's CEO?

Mr. Adrian H. B. Gottschalk is the chief executive officer of Foghorn Therapeutics Inc., which has about 106 employees.

What is the FHTX 52-week high?

The 52-week high for FHTX is $7.61 and the 52-week low is $1.66. The stock is currently 77.4% below its high.

Compare FHTX